Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ponatinib plus intensive chemotherapy for transformed chronic myeloid leukemia
ISRCTN98986889Phase 2Completed
- Sponsor
- University of Birmingham
- Start
- Dec 2014
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of ponatinib, fludarabine, cytarabine, idarubicin and filgrastim in chronic myeloid leukemia blast phase (CML-BP), sponsored by University of Birmingham. Primary endpoint: Complete cytogenetic response. Started Dec 2014; status: completed.
02
Drugs
ponatinibfludarabinecytarabineidarubicinfilgrastim
03
Conditions
chronic myeloid leukemia blast phase (CML-BP)
Beyond the preview
Go deeper on ISRCTN98986889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN98986889.